ridethepig | GILD 2019-nCoV Target
A good time to review the previous floor at 60.xx that we have been tracking for almost a year in GILD. Here taking the latest misses in Q4 Earnings with a pinch of salt as the red carpet has been rolled out for Gild via China. Once again another buying opportunity given the latest progress around Phase III clinical trials:
On the Remdesivir (GS-5734) side, this is their free pass into the Chinese Healthcare system. Models will need to start quickly repricing revenue from the Hep B cases in China. GILD will do the heavy lifting here, +/- $20 upside available on the headline for FDA approval which looks around the corner. Flow-wise, the initial target area from the latest technical break comes into play at 86.xx (+25% from current levels).
As usual thanks for keeping the support coming with likes, comments and etc!
On the Remdesivir (GS-5734) side, this is their free pass into the Chinese Healthcare system. Models will need to start quickly repricing revenue from the Hep B cases in China. GILD will do the heavy lifting here, +/- $20 upside available on the headline for FDA approval which looks around the corner. Flow-wise, the initial target area from the latest technical break comes into play at 86.xx (+25% from current levels).
As usual thanks for keeping the support coming with likes, comments and etc!
Note
+5% today....a very good startNote
Note
A flawless leg so far... Trade closed: target reached
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.